Missing: Avera Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Avera Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Avera Pharmaceuticals Frequently Asked Questions (FAQ)
When was Avera Pharmaceuticals founded?
Avera Pharmaceuticals was founded in 2002.
Where is Avera Pharmaceuticals's headquarters?
Avera Pharmaceuticals's headquarters is located at 4350 La Jolla Village Drive, San Diego.
What is Avera Pharmaceuticals's latest funding round?
Avera Pharmaceuticals's latest funding round is Dead.
How much did Avera Pharmaceuticals raise?
Avera Pharmaceuticals raised a total of $80.08M.
Who are the investors of Avera Pharmaceuticals?
Investors of Avera Pharmaceuticals include InterWest Partners, BTG Ventures, Bay City Capital, Frazier Healthcare Partners, Windamere Venture Partners and 13 more.
Who are Avera Pharmaceuticals's competitors?
Competitors of Avera Pharmaceuticals include AngioChem, Kythera Biopharmaceuticals, Potentia Pharmaceuticals, Galenea, Stromedix and 12 more.
Compare Avera Pharmaceuticals to Competitors
Galenea is a biopharmaceutical company discovering and developing drugs to treat schizophrenia and other central nervous system diseases. The company has developed technology, the MANTRA (Multiwell, Automated NeuroTRansmission Assay) system, which enables direct high throughput screening of synaptic function in cultured primary neurons from mice and rats, and in neurons derived from human induced pluripotent stem cells. The company is using the MANTRA system to characterize synaptic dysfunctions in disease models and to identify signatures of therapeutic compound classes.
CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.
Sarossa, formerly Antisoma, is an investment holding and management company whose principal activity is investment in and growth and development of businesses which present opportunities for value creation.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Paratek is a biopharmaceutical company focused on the development, and commercialization of innovative antibiotics. Paratek's lead product candidate, omadacycline, is a novel tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Omadacycline has Special Protocol Assessment agreements with the U.S. Food and Drug Administration for the phase 3 trials planned in ABSSSI and CABP.
AngioChem is a clinical-stage biotechnology discovering and developing drugs that are capable of crossing the blood-brain barrier to treat brain diseases. The company's EPiC platform aims to solve the key problem for crossing the blood-brain barrier by developing drugs that use a receptor-based approach.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.